New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 20, 2014
06:08 EDTFOLDAmicus Therapeutics reports positive Phase 3 data from Fabry study
Amicus Therapeutics announced positive 18-month data from its second Phase 3 study of the oral small molecule chaperone migalastat HCl - "migalastat" - in Fabry patients with amenable mutations. Study 012 compared oral migalastat to standard-of-care enzyme replacement therapies for Fabry disease. The co-primary outcome measures were the mean annualized changes in estimated glomerular filtration rate and measured GFR assessed by descriptive comparisons of migalastat and ERT over 18 months. Migalastat had a comparable effect to ERT on patients' kidney function as measured by the change in eGFR and mGFR. Levels of plasma lyso-Gb3, an important biomarker of disease, remained low and stable in patients with amenable mutations who switched from ERT to migalastat. Migalastat was generally safe and well-tolerated.
News For FOLD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 31, 2015
16:23 EDTFOLDOn The Fly: Top stock stories for Monday
Subscribe for More Information
06:30 EDTFOLDAmicus to host conference call
Subscribe for More Information
06:03 EDTFOLDAmicus agrees to acquire Scioderm
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use